Institutional Investors Give Mixed Message on Cybersecurity

In a recent survey, institutional investors said they both care very deeply about cybersecurity, but aren't making a significant investment on prevention technologies.

image-of-a-hacker-cybersecurity

The open discussion of cybersecurity-related concerns on the buy side has seemingly gone from close to nil to being on everyone's lips within the span of two years. Go to any industry conference nowadays and hedge fund managers are all too happy to broach the sensitive subject.

There's no doubt that it's a concern, but just how serious a concern is debatable. When divvying up an IT budget, is it more important than investing in new trading technologies or updating legacy systems? Is it more

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

Firms step up non-compete use to protect tech, data IP

US states are increasingly banning or limiting the use of non-compete contracts, but financial firms are using them more frequently to safeguard proprietary tech and data assets—including the knowledge of the individuals who work on them.

Waters Wrap: Examining ASX’s CHESS do-over

The Australian exchange was the first exchange to be all-in on DLT—and the project failed. Anthony speaks with ASX’s Tim Whiteley to discuss the lessons learned and why he thinks the second attempt will succeed.

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here